Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs), a class of small molecule drugs that harness the body's natural protein destruction mechanisms to selectively eliminate therapeutically relevant proteins. The company employs its proprietary Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform, which integrates artificial intelligence and experimental tools to enable target-centric discovery and rational design of MGD product candidates. Key pipeline assets include MRT-2359, an orally bioavailable MGD targeting the GSPT1 protein for potential treatment of MYC-driven tumors such as metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Additional candidates like MRT-6160 and MRT-8102 address needs in oncology and autoimmune diseases. Monte Rosa Therapeutics, Inc. operates within the biotechnology and medical research sector, advancing novel therapeutic modalities to tackle serious diseases through precision protein degradation.